title: Minimal residual disease: what are the minimum requirements?
authors.affiliation: Center for Cancer Research, National Institutes of Health, Bethesda, MD.
authors.forename: Mark
authors.initials: M
authors.lastname: Roschewski
authors.forename: Maryalice
authors.initials: M
authors.lastname: Stetler-Stevenson
authors.forename: Constance
authors.initials: C
authors.lastname: Yuan
authors.forename: Sham
authors.initials: S
authors.lastname: Mailankody
authors.forename: Neha
authors.initials: N
authors.lastname: Korde
authors.forename: Ola
authors.initials: O
authors.lastname: Landgren
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D018365:Neoplasm, Residual / Q000188:drug therapy* / Q000473:pathology*